What is the half-life of sertraline (Zoloft) in a typical adult patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 24, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Sertraline Half-Life

Sertraline has an elimination half-life of approximately 26 hours (range 22-36 hours), allowing for once-daily dosing. 1, 2

Pharmacokinetic Details

The FDA-approved drug label specifies that the plasma terminal elimination half-life of sertraline ranges from 22 to 36 hours in adults, with steady-state achieved after approximately 1 week (7 days) of daily dosing. 1

Active Metabolite Considerations

  • N-desmethylsertraline, the primary metabolite, has a significantly longer half-life of 62 to 104 hours, though it is substantially less pharmacologically active than the parent compound. 1
  • This metabolite accumulates to greater concentrations in plasma than sertraline itself at steady state, exhibiting 5 to 9-fold increases in pharmacokinetic parameters between day 1 and day 14. 1

Population-Specific Variations

Pediatric Patients

  • Children aged 6-12 years show a mean half-life of 26.2 hours. 1
  • Adolescents aged 13-17 years demonstrate a mean half-life of 27.8 hours. 1
  • These values are comparable to adults (27.2 hours), though pediatric patients metabolize sertraline with slightly greater efficiency when adjusted for body weight. 1

Elderly Patients

  • Sertraline plasma clearance is approximately 40% lower in elderly patients compared to younger individuals, suggesting steady-state is achieved after 2 to 3 weeks rather than the typical 1 week. 1
  • Despite reduced clearance, the elimination half-life remains approximately 26 hours, similar to younger adults. 3

Hepatic Impairment

  • Patients with mild liver impairment (Child-Pugh scores 5-8) show approximately 3-fold greater sertraline exposure due to reduced clearance, necessitating lower or less frequent dosing. 1

Renal Impairment

  • The half-life and pharmacokinetics remain unaltered in patients with mild to severe renal impairment, including those on hemodialysis, as sertraline is extensively metabolized and renal excretion of unchanged drug is minimal. 1

Clinical Implications for Discontinuation

  • Due to sertraline's relatively short half-life compared to fluoxetine, it requires careful attention during discontinuation to avoid withdrawal symptoms. 4
  • When switching to an MAOI, a washout period of 5-7 days minimum (potentially extending to 2 weeks) is recommended to prevent serotonin syndrome. 5
  • At low doses, twice-daily dosing may be required in youth due to the shorter half-life relative to fluoxetine. 4

References

Related Questions

What lab tests are recommended for patients taking sertraline (Selective Serotonin Reuptake Inhibitor - SSRI)?
What is the best plan to taper off sertraline (Zoloft) for a patient taking 150mg for 4 years?
What is the duration for sertraline (selective serotonin reuptake inhibitor) to be completely eliminated from the system?
What is the onset and duration of action of sertraline (Selective Serotonin Reuptake Inhibitor) in an adult patient with depression or anxiety, particularly when taken with Adderall (dextroamphetamine and amphetamine), and how long does it take to stop working after a single administration?
What is the half-life of Sertraline (Selective Serotonin Reuptake Inhibitor)?
What is the management strategy for a patient with an atlanto-occipital dislocation who requires a cervical collar (c-collar) for life?
When can a patient with a recent minor stroke and who underwent carotid endarterectomy 48 hours ago restart aspirin therapy?
What are the diagnostic criteria for occupational Chronic Obstructive Pulmonary Disease (COPD)?
Does initial improvement with metronidazole (antibiotic) followed by symptom recurrence after stopping it, along with use of famotidine (histamine-2 (H2) blocker), rule out inflammatory bowel disease (IBD) in my case?
What are the management steps for a patient with a suspected semaglutide (GLP-1 receptor agonist) overdose, considering potential risks of severe hypoglycemia and pancreatitis?
What is the recommended initial treatment approach for a patient presenting with dermatitis, considering potential past medical history of atopic dermatitis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.